With a focus on skin diseases, Brickell Biotech's pipeline includes therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other severe skin diseases. The company's executive management team and board of directors have extensive experience in product development and global commercialization, having worked on successful products in the pharmaceutical industry. Brickell's strategy involves in-licensing, acquiring, developing, and commercializing pharmaceutical products to address unmet medical needs.